Recursion announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer, CCO. Dr. Khan will lead Recursion’s research and development and build its emerging commercial capabilities. She has also been appointed to Recursion’s Board of Directors. Dr. Khan serves as a board member for Alliance for Artificial Intelligence in Healthcare and is a Steering Committee member of the White House’s Moonshot CancerX program to enhance outcomes for cancer patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Recursion Pharmaceuticals Welcomes New Director and C-Suite Executive
- Cathie Wood’s ARK Investment buys 372K shares of Recursion Pharmaceuticals today
- Cathie Wood’s ARK Investment bought 834K shares of Recursion Pharmaceuticals
- Cathie Wood’s ARK Investment bought 733K shares of Recursion Pharmaceuticals
- Recursion Publishes Annual Environmental, Social and Governance Report
